A plausible explanation for the favorable effect of GLP-1 receptor agonists (GLP-1 RAs) on the clinical course of COVID-19 stems from an experimental study conducted in an animal model using streptozotocin-induced diabetes rats. Here, GLP1R is linked to diabetes mellitus.